NCT01957657View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Renal Insufficiency
Interventions
DRUG

BI 207127

oral administration

DRUG

faldaprevir

oral administration

DRUG

BI 207127

oral administration

DRUG

BI 207127

oral administration

DRUG

BI 207127

oral administration

DRUG

faldaprevir

oral administration

DRUG

faldaprevir

oral administration

DRUG

faldaprevir

oral administration

Trial Locations (1)

Unknown

1241.32.1 Boehringer Ingelheim Investigational Site, Kiel

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01957657 - Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients | Biotech Hunter | Biotech Hunter